Stroke, Epidemiological and Genetical Approach by Sellama Nadifi & Khalil Hamzi
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
12 
Stroke, Epidemiological  
and Genetical Approach 
Sellama Nadifi and Khalil Hamzi 
Laboratory of Genetics and Molecular Pathology,  
Faculty of Medicine and Pharmacy, 
University Hassan II Casablanca 
Morocco 
1. Introduction 
Current knowledge in genetics has began increasingly to reveal the complexity of the 
interaction between various risk factors. The purpose of this chapter is to present knowledge 
about stroke, particularly the role of genetic components as risk factors. 
Despite remarkable progress in the recent years in the field of the management and 
treatment of Cerebral Vascular Accident (stroke), the latter remains a major cause of 
mortality and morbidity in many countries. In fact, it is admitted that even though the 
majority of strokes has been not fatal sofar, it has often been responsible for functional 
deficits (motor, visual and cognitive). Stroke is very common in industrialized countries 
(Casas J et al, 2007) and is the third leading cause of death in North America, Japan and 
China (Xiao Yuxin et al, 2009) (Table 1). The annual incidence in Canada is about 1/1000, 
and soars to 10/1000 after age 65. This incidence is much higher in Europe, (7/1000 in 
France, 5.6/1000 in Portugal) (Roshan Ariyaratnam et al, 2007) (Table 2). 
Population Stroke deaths 
Per 100 000 Population 
Year of Publication * 
Spain 39.2 2005 
France 27.7 2006 
Italy 31.9 2006 
Portugal 96.1 1999 
Germany 34.5 2006 
Japan 56.3 2007 
China 160.1 2000 
Korea 93.1 2006 
Table 1. International Death Rates of Stroke (Donald Lloyd-Jones et al. 2009). 
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Population Stroke Incidence Per 1000 Publication* 
UK 1.8 Alexander H et al, 2000 
France 7.6 Lemesle M et al, 1999 
Italy 2.7 Carolei A et al, 1997 
Portugal 5.6 Correia M et al 2004 
Germany 3.5 Kolominsky-Rabas PL et al 1998 
Sweden 3.1 Johansson B et al 2000 
Table 2. Stroke incidence study in Europe (Truelsen T. et al, 2006.) 
In developing countries, this incidence is less well known due to the lack of adequate 
management of stroke patients. However, the data currently available show a frequency 
similar to those reported in some industrialized countries (Fig 1). They illustrate clearly that 
stroke is a major public health problem (Table 3). In Morocco, the incidence of stroke is 
estimated to 0.4 /1000 with 25% of death cases (Stroke colloquium 2009. 
Population Incidence Per 1000
Kuwait 0.8
Saudi Arabia 0.9
Bahrain 0.4
Qatar 0.4
Libya 0.65
Tunisia 0.54
Table 3. Stroke incidence study in Arab countries. (Hani TS Benamer et al, 2009) 
 
Fig. 1. Incidence rates of stroke in the Middle East and north of Africa (Tran J et al 2010) 
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1.1 Definition and types of stroke 
Stroke is defined by the World Health Organization (WHO), on the basis of a clinical and 
pathophysiological approach, as "a rapid installation of neurological deficit, with symptoms 
lasting 24 hours or more, associated to focal or global cerebral dysfunction, that can be fatal, 
and the apparent cause of which is vascular" (Asplund et al, 1988). This definition 
encompasses a broad category of strokes:  
Ischemic stroke: accounts for 80% of all strokes (M. Dichgans, 2007)  
Hemorrhagic stroke (20% of all strokes) (AG Thrift, 2001),  
Brain blood vessels disorders.  
Ischemic strokes are related to a complete or incomplete lack of blood supply. They include 
ischemic stroke (AIC) and transient ischemic attack (TIA).  
Stroke is thought of as a syndrome which represents a collection of disease processes all of 
which resulting in cerebral ischaemia. The different processes have different clinical 
phenotypes and different etiological mechanisms. Many symptoms can occur in stroke but 
not simultaneously. They depend on stroke localization in the brain and on vascular 
damage (Table 4). 
SYMPTOMS MANIFESTATIONS 
Cognitive 
Disturbance 
For many people, a clinical stroke elicits symptoms involving 
cognition. If one were to suffer a stroke, they may begin to feel dizzy 
or lightheaded. They may also suffer a loss of coordination, have 
trouble forming sentences or even lose consciousness. 
Vocal Disturbance Besides having a difficulty with words and sentences, it is also 
possible for a stroke to impede one’s ability to speak, causing them to 
slur or garble their words. 
Visual Disturbance For others, a stroke causes some sort of visual disturbance, including 
a blurred, doubled or darkened vision. These may either be 
momentary or prolonged. 
Mobility Issues Sometimes, a stroke causes sudden mobility issues, triggering a 
paralysis or numbness to either the right or left side of the body. 
Headaches Though a headache alone is not a sure sign one is having a stroke, it 
is one of the common symptoms, especially when accompanied by 
pain or stiffness within the neck and face as well as digestive distress. 
Digestive Distress Often associated with the symptom of a headache, a stroke can cause 
one to experience a sudden nausea that often triggers vomiting. 
Table 4. Clinical Stroke Symptoms (American Society of Neurology, 2007) 
The International Classification TOAST (Table 5), classified strokes into five groups based 
on etiologic mechanisms (Adams et al, 1993). A subtype classification has been 
recommended for genetic association studies (Dichgans et al, 2005). Increasing evidence 
suggests that different subtypes of stroke may have both different degrees of heritability 
and genetic risk factor profiles. 
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Etiology Caractéristique REF 
Atherosclerosis The arteries of large and medium caliber seats of 
choice: the origin of the internal carotid artery, the 
carotid siphon, the origin and termination of the 
vertebral artery and the aortic arch. 
(Markus et al 
2001). 
Lacunar Stroke Occlusion of these arteries is responsible for brain 
deficiencies (small deep infarct <1.5 cm in diameter). 
They are located in the subcortical areas, mainly in the 
basal ganglia, capsules, and the brain stem). It has been 
suggested as an explanation to the thrombosis process, 
an overactive clotting in predisposed patients or an 
abnormality in blood vessels.  
(Ward et 
Brown, 2002 
Cardioembolic 
Stroke 
Heart diseases that can cause embolic ischemic stroke 
are numerous. Atrial fibrillation is the heart disease 
most commonly involved (50% of cases), followed by 
ischemic heart disease and valvular heart disease. 
(Warlow et al 
2001 
Indefined 
Stroke 
Many other conditions may be responsible for stroke 
such as arterial dissection, arterial different nature 
dysplastic, inflammatory or infectious diseases or 
blood clotting abnormalities 
(Milandre et 
al 1998). 
Table 5. Stroke international Classification TOAST (Dichgans, 2004). 
1.2 Stroke pathophysiology 
In the medical literature, the term stroke refers to different events with a common 
pathophysiology, associated to subclinical atherosclerosis, or thromboembolic disease 
(MTE). As a multifactorial disease, stroke results from the synergistic combination of several 
risk factors, some of which are still unknown. (Fig 2) 
In ischemic strokes, reduced blood flow causes a set of events that influence the severity of 
cerebral infarction (Lawrence R. Wechsler et al, 2011). These events are the result of 
interaction between vascular and cellular elements which lead to the release of amino acid 
neurotransmitters and to the increase in circulating calcium and free radicals. In addition, 
oxidative stress and inflammation contribute to the process of cellular damage and 
ischemia. These events have contributed to the emergence of the new concept 
"neurovascular unit" including astrocytes, neurons and vascular structure.  
Studies of the experimental model and the analysis of brain imaging showed that brain 
damage depends on the infarction’s duration. Thus, the areas affected by the infarct remain 
viable for 24 hours with the possibility of recovery after revascularization.  
A phenotypic complexity is added with a gene-gene, gene-environment interactions 
component. The identification of environmental and genetic factors that predispose to stroke 
is a major research target for a better understanding of the pathophysiological mechanisms 
of the disease and for modulating its prevention and treatment.  
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1.3 Risk factors 
1.3.1 The traditional risk factors  
Age is the most important risk factor. The incidence of stroke doubles in men and women 
after 55 years of age (Wolfe 2000; Yannick Bejot, 2007). Smoking appears to increase the risk 
of stroke (MP Jones, 1990; Anthony Behin, 2002). However, this risk is reversible after 5 
years of cessation. Tobacco may act through different mechanisms including endothelial 
cytotoxicity, mitogenic effect on the media, platelet activation, blood hyperviscosity, and 
lowering HDL blood rates (Bhat, VM, 2008). Alcohol increases the risk of hemorrhagic 
(relative risk × 6) or ischemic stroke (relative risk × 3) (Lowenfels, Albert B., 2000, Hart C, 
1999). In addition, dietary factors play a role as well. A diet high in cholesterol, saturated fat 
and low in fruits, vegetables and fish increases the risk of stroke (Brigham and Women's 
Hospital. 2005), while a large consumption of vitamin C and folate would reduce its impact 
by an anti-oxidant effect and the reduction of homocysteine concentration. (Homocysteine 
Lowering Trialists' Collaboration, 1998). Studies, cohort and case-control, demonstrated that 
lack of exercise is associated with an increased risk of stroke. Such an effect could act, at 
least partially, by reducing blood pressure. (Chong Do Lee, 2003). Ethnicity: it is admitted 
that there is a genetic and environmental heterogeneity between races (Jun Z. Li, 2008, Neil 
Risch, 2002). Significant differences in incidence and stroke subtypes distribution have been 
reported among different ethnic groups (Dawn M. Bravata, 2005). The incidence is greater 
among African Americans and African Caribbeans versus Caucasians in the United 
Kingdom (Gillum et al, 1999). Personal or familial history is the best documented risk factor. 
In fact, the familial forms of stroke have been known since a long time (Voetsch B et al. 2003; 
Hassan A, 2002). The risk of stroke is higher in people with family history. (Duanping Liao, 
1997). Hypertension is a major risk factor, it is present in 40-85% of patients with cerebral 
infarction and in 80% of those with a cerebral hematoma (Hu G, Sarti C, 2005) regardless of 
sex and age (Collins et MacMahon, 1994; Niclot P, 2003; HironoriImano, 2009) Similarly, 
diabetes mellitus increases by 2-5 the risk of stroke (B Stegmayr, 1995) (Mats Eliasson, 2003, 
Hu G, 2005, A Rautio, 2008). The increase in total cholesterol and low density lipoprotein 
(LDL-C) was strongly correlated with the risk of ischemic heart disease. (Toth PP , 2005).  
1.3.2 The emerging risk factors 
A number of case-control studies have shown an association between infection and acute 
ischemic stroke (Grau et al. 1995; IY Bova, 1996; Benoît Guillon, 2003; A. Paganini-Hill, 
2003). The association is not specific to a particular type of infection resulting in a 
prothrombotic state and acute endothelial dysfunction (HC Emsley, 2008). Many cross-
sectional and prospective studies have shown that chronic inflammation is a risk factor and 
suggest to assess this risk by measuring C-reactive protein and proteins of the inflammatory 
reaction (PIR), (Danesh et al. 2000, Ridker et al. 2000). This systematic search does not meet 
the consensus of professionals (Fifth Conference of the American Heart Association '(AHA) 
(Pearson et al, 2004). Other factors including psychosocial factors and some hormonal 
treatments have been implicated. Currently, there is a recent increasing interest in adhesion 
molecules such as the vascular endothelial growth factor (VEGF). It is one of the main 
factors controlling the development and maintenance of the vascular system in humans 
(angiogenesis). Indeed, high levels of circulating VEGF have been observed in cases of 
ischemic diseases such as stroke [Hojo et al. 2000; Blann et al, 2002). Currently targeted 
therapies, using VEGF, are undergoing clinical trials (Buysschaert et al, 2007). 
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Fig. 2. Synthesis of stroke risk factors 
2. Genetics of stroke 
The genetics of complex diseases has known a great progress in recent years. The” Human 
Genome Project” is an international initiative that has enabled the sequencing of the human 
genome in its entirety as well as the discovery of SNP (Single nucleotide polymorphisms) 
which had a great success for association studies (Fig 3). The second initiative was the 
"HapMap project” which helped to develop a haplotype map of the human genome and 
allowed to describe the most common polymorphisms and the linkage disequilibrium 
blocks. It is currently a key for conducting further research on new genes and on both their 
association to disease and their response to drugs. 
 
Fig. 3. Results of the association of stroke with SNP tested in GWAS (GWAS project,2009) 
These risk factors are either genetic or constitutional and therefore can not be modified or 
environmental and therefore modifiable 
Predisposing risk factors  
 
 potentiat or have an effect 
when combined with 
major risk factors 
The major risk factors 
 
 have a multiplier effect 
on cardiovascular risk 
independent of other risk 
factors 
The emerging risk factors 
 
 associated with an 
increased risk but the 
degree of accountability 
and / or the mechanism of 
action are unknown to 
date 
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Apart from some rare Mendelian forms, most strokes are considered as multifactorial 
disease. The hypothesis of a genetic origin of stroke was based mainly on the observations of 
several family cases with a non-Mendelian transmission. In the Framingham project, the 
existence of a family history (paternal or maternal origin) of stroke was associated with an 
increased risk of this disease in the descendants (D. Kiely Ket al, 1993). This familial 
aggregation could be only the consequence of conventional risk factors like hypertension, 
diabetes and hypercholesterolemia. The strongest evidence has been reported by twins 
studies, and animal models (Rubattu S et al, 1996) (Table 6). These studies showed that the 
prevalence of stroke was multiplied by five in monozygotic twins compared to dizygotic 
(Flossmann E et al 2004, Jeff s Bet al 1997, Brass LM and al,1992). 
Type of study (n) Odds ratio (95% CI) p-value Stroke subclassified 
Twin studies  1.65(1.2-2.3) 0.003 No 
Cohort studies  1.30 (1.2-1.5) <0.00001 2 studies 
Case-control studies  1.76 (1.7-1.9) <0.00001 15 studies 
Table 6. Odds Ratios of a positive family history in different types of studies (Flossmann E et 
al 2004) 
2.1 Rare Mendelian etiologies responsible for stroke 
Many monogenic Mendelian diseases, be they autosomal dominant, autosomal recessive or 
X-linked, may be complicated by stroke in young patients without known risk factors (s Jeff 
B, 1997, Rolfs A et al, 2005, JA, Hess et al, 2006) (Table 7). Knowledge of these Mendelian 
forms is important. It helps in genetic counseling to identify patients at a presymptomatic 
stage in families with risk factors and, to discuss a preventive approach or treatment. 
If expressed in the homozygous state, stroke may occur at an early stage (sometimes in 
infancy). Whereas, in the heterozygous state, the consequences of the genetic defect may 
be mild or even indistinguishable from conventional risk factors’ effects. (Perry IJ et al. 
1995.). Apart from this disease, cerebral autosomal dominant arteriopathy (CADASIL), 
sickle cell disease, Fabry disease (deficiency of lysosomal alpha-galactosidase) and 
mitochondrial diseases as MELAS syndrome are probably the most common metabolic 
causes of stroke. 
CADASIL: The cerebral autosomal dominant arteriopathy with leukoencephalopathy and 
subcortical infarcts is a hereditary autosomal dominant cerebral arteriolopathy. Notch 3 
gene was located on chromosome 19 (Tournier-Lasserve E, 1993), and the first mutations 
were identified in 1996 (Joutel A, 1996). The disease has been described in different families 
of European, African, North African, American (Arcos-Burgos OM, 2001), Indian, and Asian 
origin (Kotorii S, 2001). But its prevalence remains largely under-estimated, about 1 to 
24,000. It occurs on an average of 42 years of age (Chabriat H, 1996, Chabriat H, 1997, 
Chabriat H, 1995), with extremes of 20 and 65 years (Chabriat H, 1995, Desmond DW, 1999, 
M Dichgans, 1998). 
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 diseases Frequence  transmi
ssion 
G
E
N
E 
 
metabolic 
diseases 
 -Fabry disease ( Neuropathic pain, 
cardiac failure, cataract, renal failure, 
reduction of ǂ-Gal enzyme activity, 
mechanisms of ischemic stroke 
unknown 
 -Mitochondrial diseases (MELAS, 
Development delay, sensorineural 
hearing loss, short stature, seizures, 
migraine. Pathophysiolog disruption of
the blood-brain barrier a decrease in 
cerebral blood flow autoregulation of 
primary defects in neuronal oxidative 
metabolism 
- homocystinuria, 
-sulphite oxidase deficiency  -
aciduriesméthylmalonique, propionic 
 Frequent  
 Frequent  
 
Frequent 
Frequent? 
Occasional  
XL 
Mat. 
 
AR  
MT,AD
,AR 
AR 
 GAL 
Mitoc
hondr
ial 
Coagulopathies : deficiency of factor V Leiden (resistance 
to activated protein C) Sneddon's 
syndrome (familial syndrome of 
antipholipides)  fibrinogen 
deficiency deficiency of factor VIII, IX, 
X and VIII  deficit in protein C, S  
Frequent? 
Frequent 
Frequent 
Occasional 
AD 
AD  
AR 
ARLX,
AR 
AD 
  
neuro-cutaneous 
syndromes 
Telangiectasies heorragic hereditary 
(Rendu-Osler-Weber) 
 -syndrome de Bannayan-Zonana 
 -sclérose tubéreuse de bourneville 
 -neurofibromatose de type I 
 -syndrome de Van Hippe I-Lindau  
 Frequent  
 Occasional 
 Rare 
 Rare 
 Rare 
AD 
AD 
AD 
AD 
AD 
  
Primary disease 
of the cerebral 
vessels 
fibromuscular dysplasia pseudo - 
xanthoma type I  -Ehlers-Danlos 
disease (particularly type IV)  
cerebral-amyloidosis Icelandic type 
(deficiency cystatineC) Dutch type (B 
deficiency protein precursor amyloidal,
APP B) cerebral vascular 
malformations, arterial dissection, 
familial forms of cavernous 
angioma adult polycystic kidney 
disease (APKD1 and APKD2) 
syndrome of arterial dissections and 
lentigines 
Frequent  
Frequent  
Frequent  
Frequent  
Frequent  
Rare ? 
Rare  
Frequent  
AD 
AD, 
AR 
AD, 
AR 
AD 
AD 
AD 
AD 
AD 
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CADASIL Migraine with aura is the principal 
sign, PATHOPHYSIOLOGY abnormal 
drainage of the portion of the Notch 
extramembranous 3 
protein accumulation of the fragment 
extramembranous vessels 
Frequent  AD  NOT
CH3 
Sickle-cell disease Clinical feature Pain crisis, bacterial 
infection, VasoOclusive Crisis, pul  
Pathophysiology Deformation of red 
blood cell intimal hyperplasia 
proliferation of smooth muscle cells 
thrombosis. 
monary and abdominal crises, 
anaemia, myelopathy, seizure 
Frequent  AR  HBB 
Table 7. Etiologies responsible for rare mendelian stroke (Natowicz M et al, 1987) 
Sickle cell disease is a common cause of stroke in children (JA Switzer, 2006), either in its 
homozygous or compound heterozygous form with hemoglobin C (HbC) or ǂ-thalassemia 
(Old J. 2002). Hemoglobin S is due to a mutation by substitution of adenine for thymine in 
codon 6 of the ǃ-globin gene on chromosome 11p15.4, resulting in the substitution of a 
valine by a glutamic acid in the protein chain. This alteration of the protein causes a 
deformation of the red cell that becomes sickle-shaped. Brain stroke appears to be a 
consequence of an abnormal interaction between sickle red blood cells and vascular 
endothelium (JA Switzer, 2006; Hebbel RP, 2004). The sickled red cells tend to clump 
together and adhere to the endothelium. The endothelial activation further promotes 
remodeling of the arterial wall and vascular disease. The typical atherothrombotic stroke is 
often located in the internal carotid artery and the proximal, middle and anterior portions of 
cerebral arteries. It is associated with hyperplasia of intima, fibroblasts proliferation and 
smooth muscle cells. (Stockman JA et al 1972). Many patients develop lacunar small-vessel 
disease (JA Switzer, 2006; J Schatz, 2002).  
Fabry disease is a lysosomal disease, due to a deficiency of ǂ-galactosidase A enzyme 
(GLA). Most patients are carriers of missense and nonsense mutations, large and small 
rearrangements or splicing defects in the coding region of ǂ-galactosidase gene on the X 
chromosome (GLA) (Desnick et al 2001, Schaefer, 2005; Human Gene Mutation Database). 
Clinical signs include an acroparesthesia, angiokeratoma, and hypohidrosis, which often 
develop in childhood or adolescence before the systemic complications leading to heart and 
renal failure and ischemic stroke (Rolfs A et al 2005; Crutchfield KE et al 1998, Grewal RP et 
al 1994; Mitsias P et al, 1996). Ischemic stroke predominates in the vertebrobasilar circulation 
(Rolfs A, 2005). 
MELAS syndrome: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like 
episodes, is a mitochondriopathy caused by many mutations, transmitted by maternal 
inheritance in mitochondrial DNA (Pavlakis SG, 1984, Martinez-Fernandez E, 2001). Over 
80% of patients carry the A3243G mutation; an A to G transition at position 3243 of the gene 
MT-TL1. MELAS syndrome is associated with various symptoms. However, in 
monosymptomatic cases, ischemic stroke is the only existing expression (Martinez-
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Fernandez E, 2001). In MELAS, the episodes of ischemic stroke are different from those of a 
typical cerebral infarction with the cortex being always involved.  
Primitive genetic diseases of the cerebral vessels: an increasing number of genetic diseases 
of the cerebral vessels responsible for stroke have been identified in the last few years. 
Fibromuscular dysplasia is characterized by the presence of dilatations in small and 
medium arteries due to the destruction of the media, fibrosis and muscular hyperplasia. The 
occurrence of aneurysm rupture is a relatively common event in various forms of Ehlers-
Danlos disease; especially type IV that is characterized by a deficiency of collagen type 3. 
Some forms of amyloidosis are characterized by a predominantly cerebral localization of 
amyloidal deposits in the vessels causing hemorrhagic or ischemic stroke. These disorders 
are genetically heterogeneous; some are due to mutations in cystatin C (an inhibitor of 
several cysteine proteinases), others are due to mutations in the precursor of the beta-
amyloid protein (beta-APP) (Levy E et al. 1990, M. Abrahamson, 1992).  
2.2 Stroke model of multifactorial disease with polygenic component 
More than 2300 candidate polymorphisms are currently listed in association with stroke 
(Matthew B et al, 2010). These factors have been listed on the bases of their involvement in 
known metabolic pathways or through pangenomics studies. Most of them have been 
analyzed in different populations by association studies. The genes studied are typically 
those involved in the coagulation (Fig 4), homocysteine and lipid metabolism. Among those 
genes, the most explored with consensus were: FV, FII, MTHFR, ApoE, ACE (Fig 5) and 
fibrinogen, PAI1. Others have been explored without consensus (Enos, PON, LPL, FGA / 
FGB / FGG, F7, F13A1, vWF, F12, SERPINE1, ITGB3, PLA2, ITGA2B, ITGA2, GP1BA, AGT, 
NOS3, LPL, PON1, PDE4D, ALOX5AP, MTR, CBS, NINJ2) (Bersano et al. 2008). The results 
published today are often controversial depending on the population studied, the age of 
patients and stroke subtypes.  
a- Factor V Leiden Mutation: is one of the most studied thrombotic variants. It is the main 
genetic risk factor for deep vein thrombosis. (JP Casas, 2004; Ye Z, 2006, Paluku T, 2011). 
Several meta-analyses were conducted to study the association between FVL and stroke. 
The results are controversial and are population age dependent; this Association was absent 
in Morocco (Paluku et al, 2011), weak in Asia (Jul K, 2002, Kim RJ, 2003). It is found highly 
significant with an OR of 1.33 (95% CI, 1.12 to 1.58) in the Caucasian population (Casas JP, 
2004, Paul Bentley et al.).  
The data published on the FV Leiden mutation showed a great diversity in geographical 
repartition. it is very common in Europeans, with a north-south gradient: 4.4% in the UK 
versus 1.7 % in Italy and is absent in sub-Saharian Africans and East-Asians. For Arab 
populations in the eastern basin of the Mediterranean, this mutation is high especially in 
Jordan (12.3%) (AWID, 1999), Syria (13.6%) (Irani-Hakim, 2000) and Lebanon (14.2%) (Irani-
Hakim 2000, 2002 Tamim). Prevalence decreases as the distance from these regions of the 
Mediterranean basin increases. It is present in Tunisia, Algeria, and absent in Morocco 
(Mathonnet F, Nadifi S. et al, 2002). This geographical difference in the Maghreb could be 
explained by the region’s history, including the presence of the Ottoman Empire (Turkish) 
since the XVIth century in Tunisia and Algeria (Cavalli et al, 1994), but not in Morocco 
(Mathonnet F, Nadifi S 2002). This mutation is probably due to a founder effect, which 
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would have occurred in the eastern Mediterranean sea, 21000 to 34000 years ago (Zivelin 
1997) and spread across the migration flows to other parts of the world (Castoldi 1997, Irani 
Hakim, 2000).  
b- Mutation G20210A of prothrombin gene: Prothrombin G20210A mutation is considered 
as the second cause of inherited thromboembolic disease. This mutation is found at the 
heterozygous state in 4 to 8% of subjects with a first episode of venous thrombosis. The 
estimated relative risk is 2-7 times higher in carriers (De Moerloose, 2000, Emmrich 2001, 
Paluku et al, 2011). The homozygous forms are rarely observed (0.014% -0.0025%) (Poort SR, 
1996) and risk associated with homozygosity is currently unknown. The mechanism of 
hypercoagulability is due to an increase in the formation of thrombin. However, there are 
conflicting results in the role of the G20210A prothrombin gene in ischemic stroke 
pathogenesis.  
c-: fibrinogen: Studies have shown a strong link between high plasma fibrinogen and stroke 
(Wilhelmsen L, 1984 Gregory W. Albers 2009). The relative risk was estimated to 2.06 (1.83-
2.33) (CO Fibrinogen Studies, 2005). This relationship is controversial because the levels of 
fibrinogen are influenced by tobacco, obesity, diabetes, inflammation and infection (L 
Wilhelmsen, 1984, Rothwell PM, 2004).  
 
Fig. 4. Schema of cascade of coagulation with different factors 
d- Mutations in the PAI1 gene: The Plasminogen activator inhibitor type 1 (PAI1) is a potent 
inhibitor of fibrinolysis (Dichgans et al, 2008). It was shown that a high activity of PAI1 is 
associated with an important cerebral risk and coronary vascular disease (Casas JP et al 
2004). The 4G/5G polymorphism in the PAI1 gene promoter is most frequently studied in 
association with stroke (Roshan A et al, 2007). The data of association studies (Case-control) 
were not unanimous about the involvement of the 5G polymorphism in stroke (Dichgans, 
2008). 
e- Molecular mechanism of C667T Variant of MTHFR gene: The 5, 10-
methylenetetrahydrofolate reductase (MTHFR) is an enzyme catalyzing the reduction of 5, 
10 - methylenetetrahydrofolate (MTHF), to 5-MTHF, which is the predominant form of 
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folate. The MTHFR gene is located in 1p36.3 (Goyette et al, 1994). It comprises 11 exons and 
extends over a length of 2.2 Kb (Goyette, 1998). The C667T mutation makes the protein 
thermolabile and its enzymatic activity is reduced by half (Frost, 1995). The presence of this 
mutation in the homozygous state affects folate metabolism and induces a moderate 
elevation of plasma homocysteine. The C677T mutation of the MTHFR gene has been 
extensively explored in association studies with stroke; based on strict criteria such as age, 
stroke subtypes. An association was found between the TT genotype and stroke; it was 
stronger when the subject is young, with significant OR (Corin 2005, Xiao2009, KT Moe, 
2008, Paluku, Nadifi S. et al 2010). Subjects with the TT genotype had higher homocysteine 
levels and fewer circulating folate than those with CC genotype. (BM McQuillan, 1999; 
Deloughery TG, 1996, Ma J, 1996, Schwartz SM 1997, L Brattstrom, 1998)) 
f- Polymorphism insertion/deletion (I/D) ACE gene: The insertion/deletion polymorphism 
in the angiotensin-converting enzyme gene (ACE) is one of the most common genetic 
variants studied in relation with atherosclerotic vascular disease. A relative risk of 1.5 to 4 
had been reported in association between this polymorphism and ischemic stroke 
(Cambienet al. 1992). However, other studies have failed to find significant association. This 
result can be explained by the high frequency of this polymorphism in the population (> 
90%). (Catto A, 1996, Dikmen M, 2006, Doi Y, 1997, Pera J, 2006, Tuncer N, 2006, Gao X, 
2006; Lin JJ, 2000, Pullicino P, 1996, Ueda S, 1995) 
g-The gene for apolipoprotein E (ApoE): The apolipoprotein E gene is one of the most 
widely studied in vascular and neurodegenerative disease (JE Eichner, 2002). Several meta-
analyses reported controversial results between the ApoE4 allele and the risk of ischemic 
stroke. This association appears to be weak in Asian patients (Xi, 2009) (Benerje, 2007), 
absent in Italy and Turkey (Cerrato P, 2005, Duzenli S, 2004),). So, the exact role of Apo E4 
polymorphism in ischemic stroke is uncertain probably due to the variability of its 
distribution in populations around the world.  
 
Fig. 5. Panel of 5 Genetic Factors with Degree of Association With Stroke. (Nadifi et al, 2011, 
Indian Journal of human genetics IJHG57-11) 
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h-the Phosphodiesterase 4D gene (PDE4D): The PDE4D is the first gene found by linkage in 
stroke Iceland patients; an association of SNPs of the PDE4D (83T / C) and (-889C / T) was 
reported, with an increased risk of developing stroke (Nan et al Li1. 2010). Other studies 
have led to conflicting results. There are few studies limited to a small number of patients. 
Thus, it is premature to conclude the association of PDE4D gene with stroke and its role in 
the stroke pathogenesis. In fact, it would be interesting to study larger series of different 
populations. Therefore, experimental studies on the function of PDE4D will help to unveil 
the mystery (E Lõhmussaar et al, 2005) 
I-5-lipoxygenase-activating protein gene" gene: The locus13q12 ALOX5AP gene is involved 
in the metabolism of leukotrienes and atherosclerosis. HAPA is the most frequent 
polymorphism described. It has been associated with increased risk in stroke compared to 
controls (Helgadottir A, 2004). These results were found only in a Scottish study 
(Helgadottir A, 200, Meschia JF, 2005). 
j-Other candidate genes and pathways have been studied for possible association with 
ischemic stroke. They are listed in the webtable (www.Genome.org) or discussed in reviews 
(Table 7). Those genes are involved in inflammation (interleukine 1, interleukin 6, TNF, Toll-
like receptor 4, P-selectin and E-selectin, C-reactive protein), and lipid metabolism 
(apolipoprotein E, paraoxonase III; ApoA1, Apo A5…). (Table 8) 
3. Conclusion and outlook  
Stroke is an excellent research model for complex multifactorial disease; involving many 
risk factors (constitutional, environmental and genetic). 
Historically, the epidemiological studies were based on a 'candidate gene' approach, defined 
by the knowledge of pathophysiology (table 9). The advent of Genome-Wide Scan (GWS) 
had permitted the emergence of new hypothesis in physiological pathways and novel 
biomarkers. The Genome Wide Association Studies had revolutionized the understanding 
of disease etiology and risk factors. However, they are still in their beginning and haven’t 
yet incorporated complex statistical data that woul allow us to understand gene-gene 
(epistatsis) and gene-environment interactions. 
These studies could be a major challenge that requires the collaboration of several centers 
and the elaboration of large clinical and epidemiological databases. 
The genetic origin of stroke had been widely studied but many questions are still unsolved. 
Among them, the cumulative effect of identified mutations, the gene-gene, gene-
environmental interactions that modulate the genetic effect represent a big mystery that still 
needs to be elucidated. The underestimated heritability of the risk factors is probably due to 
a deficiency in the clinical information and genetic modeling. The influence of all these 
factors is not only additive, or dominant/recessive, but also interactive. Epidemiological 
studies had largely explored the genetic mechanisms in a classical approach based on 
pathophysiology knowledge. But, there are probably other unknown mechanisms that could 
be explained by « pangenomics hypothesis free ». In this way, many metabolic pathways 
and novel variants involved in vascular diseases have been identified. Currently, only 12% 
of SNPs are located in coding regions. The majority of SNP (40% in intergenic regions, 40% 
in introns) may have a role in regulating the expression of these genes (Hardy et al. 2009, 
Hindorff et al. 2009]). In addition, gene-environment interactions are largely missed in the 
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genome-wide approaches. The presence of functional genes is not sufficient to the occurring 
of a subject phenotype in the absence of environmental stimuli. 
 
Table 8. Final panel of genetic factors with different degrees of association with stroke. (A. 
Bersano, et al 2008) 
Finally, the understanding of stroke physiopathology and genetics requires developing 
more efficient tools: 
Implementation of an epidemiological case-control study focusing on large populations in 
different ethnic groups. 
Genotyping multiple deleterious polymorphisms in several genes. 
In perspective, the development of pharmacogenetics has emerged recently as a promising area 
of research. For example, warfarine, an oral anticoagulant, is prescribed to millions of patients 
for cardiovascular problems and that causes many difficulties to determine the effective dose. 
The polymorphisms in the CYP2C9 and VKORC1 gene influence individual susceptibility 
response to warfarine. The genotyping of VKORC1 gene showed a strong association and 
researchers started treatment strategies according to individual patients genotypes. 
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Table 9. Design of studies on molecular genetics of stroke. 
Functional candidate gene approach 
It takes into account their functions in physiological or metabolic pathways. 
It starts with a hypothesis and the association between candidate gene and phenotype is 
sought. This approach involves a study of case-control association of unrelated 
individuals. 
The study of association of a genotype or allele and complex disease with comparison of 
frequencies in patients and controls. 
In SNP association studies in several stroke criticisms were made after many difficulties 
to reproduce the results published by other researchers (Hirchhorn et al.) 
It is essential to apply strict criteria and standardized, as a good selection of genetic 
polymorphisms in which the candidate gene not only intervene in a pathophysiological 
pathway, but in which the SNP is real, supported by data on the function. 
Finally, it should have large samples for the allele frequencies and odds ratios OR 
Dichgans and Marcus, 
Positional candidate gene approach or positional cloning 
is to locate regions of the genome containing susceptibility genes without prior 
knowledge of its function, except for certain diseases only. When a connection has been 
well identified, the gene will be cloned and lsa start function can be determined (Risch, 
N. and Merikangas, KR 1996). Linkage studies are most effective for identifying genes 
that have a significant effect (Lander, E. 1994). 
The analysis of a link between two loci is tested by calculating the LOD score, a 
statistical analysis that compares the probability that the loci are linked 
More than two loci are close to each other, the less likely it is that there is a 
recombination between the two during meiosis. If they are removed, the alleles of both 
loci will be sent randomly. 
By convention, a LOD score above 3 states the obvious connections, while a LOD score 
less than -2 indicates no connection, and a score between -2 and 3 can never confirm or 
reject a bond in a single test. 
When linkage analysis is done across the whole genome multipoint LOD score is used. 
This analysis is not limited only to enumerate all the markers genetically close but 
calculates allele frequencies of the markers used. This approach by mapping the entire 
genome suggests significant LOD scores exceeding + 3.3 (Lander, ES 1994). 
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